TY - JOUR
T1 - Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation
AU - Javitz, Harold S.
AU - Zbikowski, Susan M.
AU - Deprey, Mona
AU - McAfee, Timothy A.
AU - McClure, Jennifer B.
AU - Richards, Julie
AU - Catz, Sheryl L
AU - Jack, Lisa M.
AU - Swan, Gary E.
PY - 2011/3
Y1 - 2011/3
N2 - There is a lack of evidence of the relative cost-effectiveness of proactive telephone counseling (PTC) and Web-based delivery of smoking cessation services in conjunction with pharmacotherapy. We calculated the differential cost-effectiveness of three behavioral smoking cessation modalities with varenicline treatment in a randomized trial of current smokers from a large health system. Eligible participants were randomized to one of three smoking cessation interventions: Web-based counseling (n = 401), PTC (n = 402), or combined PTC-Web counseling (n = 399). All participants received a standard 12-week course of varenicline. The primary outcome was a 7-day point prevalent nonsmoking at the 6 month follow-up. The Web intervention was the least expensive followed by the PTC and PTC-Web groups. Costs per additional 6-month nonsmoker and per additional lifetime quitter were $1,278 and $2,601 for Web, $1,472 and $2,995 for PTC, and $1,617 and $3,291 for PTC-Web. Cost per life-year (LY) and quality-adjusted life-year (QALY) saved were $1,148 and $1,136 for Web, $1,320 and $1,308 for PTC, and $1,450 and $1,437 for PTC-Web. Based on the cost per LY and QALY saved, these interventions are among the most cost-effective life-saving medical treatments. Web, PTC, and combined PTC-Web treatments were all highly cost-effective, with the Web treatment being marginally more cost-effective than the PTC or combined PTC-Web treatments.
AB - There is a lack of evidence of the relative cost-effectiveness of proactive telephone counseling (PTC) and Web-based delivery of smoking cessation services in conjunction with pharmacotherapy. We calculated the differential cost-effectiveness of three behavioral smoking cessation modalities with varenicline treatment in a randomized trial of current smokers from a large health system. Eligible participants were randomized to one of three smoking cessation interventions: Web-based counseling (n = 401), PTC (n = 402), or combined PTC-Web counseling (n = 399). All participants received a standard 12-week course of varenicline. The primary outcome was a 7-day point prevalent nonsmoking at the 6 month follow-up. The Web intervention was the least expensive followed by the PTC and PTC-Web groups. Costs per additional 6-month nonsmoker and per additional lifetime quitter were $1,278 and $2,601 for Web, $1,472 and $2,995 for PTC, and $1,617 and $3,291 for PTC-Web. Cost per life-year (LY) and quality-adjusted life-year (QALY) saved were $1,148 and $1,136 for Web, $1,320 and $1,308 for PTC, and $1,450 and $1,437 for PTC-Web. Based on the cost per LY and QALY saved, these interventions are among the most cost-effective life-saving medical treatments. Web, PTC, and combined PTC-Web treatments were all highly cost-effective, with the Web treatment being marginally more cost-effective than the PTC or combined PTC-Web treatments.
KW - Behavioral intervention
KW - Cost-effectiveness
KW - Quality-adjusted life-years saved
KW - Smoking cessation
KW - Varenicline
UR - http://www.scopus.com/inward/record.url?scp=84859261514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859261514&partnerID=8YFLogxK
U2 - 10.1007/s13142-010-0009-8
DO - 10.1007/s13142-010-0009-8
M3 - Article
AN - SCOPUS:84859261514
VL - 1
SP - 182
EP - 190
JO - Translational Behavioral Medicine
JF - Translational Behavioral Medicine
SN - 1869-6716
IS - 1
ER -